Document is current
Any future updates will be listed below
-
Authors
Xiang, Jingyu http://orcid.org/0000-0001-5524-0931
Devenport, Jessica M.
Carter, Alun J.
Staser, Karl W.
Kim, Miriam Y.
O’ Neal, Julie http://orcid.org/0000-0002-4770-8052
Ritchey, Julie K.
Rettig, Michael P.
Gao, Feng
Rettig, Garrett
Turk, Rolf http://orcid.org/0000-0003-1283-9594
Lee, Byung Ha http://orcid.org/0000-0002-4139-1226
Cooper, Matthew L. http://orcid.org/0000-0003-2395-8628
DiPersio, John F. http://orcid.org/0000-0002-0429-3133
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA210084, CA091842)
U.S. Department of Health & Human Services | National Institutes of Health (CA171963)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 26 June 2023
Revised: 1 September 2023
Accepted: 13 September 2023
First Online: 5 October 2023
Competing interests
: MYK, KWS, JO, MLC, and JFD are creators/inventors of a patent on the use of IL-7 to enhance CAR T cell function. MLC is currently employed by and has equity ownership in Wugen. JFD receives research funding from Amphivena Therapeutics, NeoImmuneTech, Macrogenics, Incyte, Bioline Rx, Wugen; has equity ownership in Magenta Therapeutics, Wugen; consults for Incyte, RiverVest Venture Partners, hC Bioscience, Inc.; and is a board member for RiverVest Venture Partners, Magenta Therapeutics. AJC is currently employed by BlueSphere Bio and has equity ownership in Wugen. GR and RT are currently employed by Integrated DNA Technologies. BHL is currently employed by NeoImmuneTech, Inc. The remaining authors declare no competing interests.
